Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748877 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia
A Phase 2 study, sponsored by NeurAxon.
- Completed
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
NCT01748877 is a Phase 2 study that has completed, run by NeurAxon. The registered enrollment target is 188 participants.
The verdict
NCT01748877, a Phase 2 study, has completed, sponsored by NeurAxon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.
Interventions
- DRUG Placebo
- DRUG NXN-462
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01748877
The ClinicalTrials.gov registry entry for NCT01748877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeurAxon, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01748877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01748877 about?
NCT01748877 is a clinical study titled "Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia". The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.
What is the current status of trial NCT01748877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2013-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01748877?
The interventions under investigation include: Placebo (DRUG), NXN-462 (DRUG).
Who is sponsoring clinical trial NCT01748877?
This trial is sponsored by NeurAxon, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.